Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes
The intrinsic role of LAMP2 in BLCA progression is clarified and MRGPRX4 modulator-2 (Mm-2), a LAMP2-binding small molecule with anti-tumor activity against BLCA, is identified as a candidate LAMP2-targeting agent acting on STING signaling via drug screening and molecular docking.